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Abstract
Background: We have recently shown that curcumin (a diferuloylmethane) inhibits growth and
induces apoptosis, and also demonstrated that TRAIL induces apoptosis by binding to specific cell
surface death receptors in prostate cancer cells. The objectives of this paper were to investigate
the molecular mechanisms by which curcumin enhanced the apoptosis-inducing potential of TRAIL
in prostate cancer cells.
Results: Curcumin enhanced the apoptosis-inducing potential of TRAIL in androgen-unresponsive
PC-3 cells and sensitized androgen-responsive TRAIL-resistant LNCaP cells. Curcumin inhibited
the expressions of Bcl-2, Bcl-XL, survivin and XIAP, and induced the expressions Bax, Bak, PUMA,
Bim, and Noxa and death receptors (TRAIL-R1/DR4 and TRAIL-R2/DR5) in both cell lines.
Overexpression of dominant negative FADD inhibited the interactive effects of curcumin and
TRAIL on apoptosis. Treatment of these cells with curcumin resulted in activation of caspase-3, and
caspase-9, and drop in mitochondrial membrane potential, and these events were further enhanced
when combined with TRAIL. Curcumin inhibited capillary tube formation and migration of HUVEC
cells and these effects were further enhanced in the presence of MEK1/2 inhibitor PD98059.
Conclusion: The ability of curcumin to inhibit capillary tube formation and cell migration, and
enhance the therapeutic potential of TRAIL suggests that curcumin alone or in combination with
TRAIL can be used for prostate cancer prevention and/or therapy.
Background
Prostate cancer is the second largest incidence among the
male populations in the US, and the incidence has been
increasing rapidly in the recent years [1]. Chemotherapy
has provided significant survival benefit in the treatment
of prostate cancer; however, it is associated with signifi-
cant normal tissue toxicity, highlighting the need for ther-
apeutic strategies that target tumor cells without
compromising normal tissue function [2]. Increased con-
centrations of cytotoxic drugs and higher dosages of irra-
diation often fail to improve the health of prostate cancer
patients, and may cause resistance to apoptosis. Thus, it is
imperative to identify anticancer agents that are nontoxic
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in tumor cells.
Epidemiological data support the concept that naturally
occurring compounds in the human diet are safe, non-
toxic, and have long lasting beneficial effects on human
health. Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-
1,6-hepatadiene-3,5-dione; diferulolylmethane], a major
constituent of the yellow spice turmeric derived from the
rhizomes of Curcuma spp., is one such compound [3]. It
has been used in Asian food for centuries [3]. Curcumin
has been reported to have several pharmacological effects
including anti-tumor, anti-inflammatory and anti-oxi-
dant properties [3-7]. Recent studies have also suggested
that it can inhibit tumor metastasis, invasion and angio-
genesis [7-11]. We have recently shown that curcumin
induces apoptosis in prostate cancer cells by inhibiting
Akt activity upstream of mitochondria, and Bax and Bak
genes completely inhibit curcumin-induced apoptosis
[12,13]. Furthermore, curcumin inhibits NFκB activity in
cancer cells [8,14] and sensitizes cancer cells to chemo-
therapy and radiotherapy [15-21].
Binding of TRAIL to its receptors TRAIL-R1/DR4 and
TRAIL-R2/DR5, both of which contain a cytoplasmic
region of 80 amino acids designated as the "death
domain", activated the extrinsic apoptosis pathway.
Death receptors DR4 and DR5 can recruit the initiator cas-
pases, caspase-8 and caspase-10, by a homotypic interac-
tion between the death effector domains of the adapter
molecule Fas-associated death domain (FADD) protein
and the prodomain of the initiator caspase, thereby form-
ing the death-inducing signaling complex (DISC). The
formation of active DISC is essential for TRAIL to transmit
apoptotic signals. We and others have shown that tumor-
selective targeting molecules such as tumor necrosis factor
(TNF)-related apoptosis-inducing ligand (TRAIL) induces
apoptosis in prostate cancer cells, both in vitro and in vivo
[22-25]. Data on experimental animals and primates led
us to believe that TRAIL has great promise as a selective
anticancer agent [22,23,26]. We have recently demon-
strated that TRAIL induces apoptosis in several prostate
cancer cells lines, but it was ineffective in inducing apop-
tosis in LNCaP cells [22,23,27]. Chemopreventive agent
curcumin has been shown to sensitize TRAIL-resistant
prostate cancer cells in vitro [28-30]. However, the molec-
ular mechanisms by which curcumin sensitizes prostate
cancer cells to TRAIL treatment are not well understood.
Angiogenesis, the formation of new blood vessels from
preexisting capillaries, is essential for tumor progression
and metastasis, and consists of a multistep process involv-
ing an array of molecular signals [31,32]. During tumor
neovascularization, multiple processes (including the
stimulation of endothelial cell proliferation, migration
and assembly; the recruitment of perivascular cells; and
extracellular matrix modeling) are involved. Ras-Raf-
MEK-ERK signal transduction pathway has been shown to
play an active role in angiogenesis. It is not clear whether
ERK plays an active role in antiangiogenic effects of curcu-
min.
The purpose of our studies was to investigate the molecu-
lar mechanisms by which curcumin enhanced therapeutic
potential of TRAIL in prostate cancer cells. Our results
indicated that curcumin enhanced apoptosis-inducing
potential of TRAIL in androgen-unresponsive PC-3 cells
and sensitized androgen-responsive TRAIL-resistant
LNCaP cells. Curcumin also inhibited capillary tube for-
mation and migration of HUVEC cells and these effects
were further enhanced in the presence of MEK inhibitor.
Thus, curcumin can be combined with TRAIL to kill
androgen-responsive and – unresponsive prostate cancer
cells.
Results
Curcumin enhances the apoptosis-inducing potential of 
TRAIL in PC-3 cells and sensitizes TRAIL-resistant LNCaP 
cells
We first measured the effects of curcumin, with or without
TRAIL, on cell viability by XTT assay (Fig. 1). Curcumin
inhibited cell viability in prostate cancer PC-3 and LNCaP
cells in a dose-dependent manner. TRAIL inhibited cell
viability in PC-3 cells (Fig. 1A) but had no effect in LNCaP
cells (Fig. 1B). Furthermore, curcumin enhanced the
inhibitory effects of TRAIL on cell viability in PC-3 cells,
and sensitized TRAIL-resistant LNCaP cells. These data
suggest that curcumin alone is effective in both PC-3 and
LNCaP cells, enhances the anti-proliferative activity of
TRAIL in PC-3 cells, and sensitizes TRAIL-resistant LNCaP
cells.
Anchorage independent colony growth is one of the char-
acteristics of cancer cells. We next measured the interactive
effects of curcumin and TRAIL on colony growth in soft
agar (Fig. 1C and 1D). Curcumin inhibited number of PC-
3 and LNCaP colonies formed in soft agar. Colonies
formed by PC-3 cells were more sensitive to curcumin
than those formed by LNCaP cells. By combination,
TRAIL inhibited number of PC-3 colonies, but had no
effect on LNCaP colonies. Interestingly, curcumin
enhanced the inhibitory effects of TRAIL on PC-3 cell col-
ony formation, and sensitized LNCaP cell colonies. These
data suggest that curcumin has ability to inhibit anchor-
age-dependent and – independent growth of prostate can-
cer cells, and can enhance the apoptosis-inducing
potential of TRAIL.
In order to examine the involvement of death receptor
pathway on interactive effects of curcumin plus TRAIL, wePage 2 of 14
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viously shown that DN-FADD blocked the interactions of
TRAIL with histone deacetylase inhibitors, resveratrol,
ionizing radiation or anticancer drugs [23,33,34]. As
before, curcumin induced apoptosis in both PC-3/neo
and LNCaP/neo cells (Fig. 1E and 1F). Curcumin
enhanced the apoptosis-inducing potential of TRAIL in
PC-3/neo cells, and sensitized TRAIL-resistant LNCaP/neo
cells to undergo apoptosis. Transfection of DN-FADD had
no effect on curcumin-induced apoptosis in both PC-3
and LNCaP cells, whereas it inhibited TRAIL-induced
apoptosis in PC-3 cells. The ability of curcumin to
enhance TRAIL-induced apoptosis in PC-3 cells, and its
sensitization of TRAIL-resistant LNCaP cells was blocked
by DN-FADD. These data suggest that death receptor path-
way is involved in transducing effects of curcumin and
TRAIL.
Interactive effects of curcumin and TRAIL on cell viability and colony formation of prostate cancer cellsFigure 1
Interactive effects of curcumin and TRAIL on cell viability and colony formation of prostate cancer cells. (A), 
PC-3 cells were treated with various concentrations of curcumin (0–30 µM) for 24 h, followed by treatment with TRAIL (25 
nM) for another 24 h. Cell viability was measured at the end of 48 h by XTT assay. (B), LNCaP cells were treated with various 
concentrations of curcumin (0–30 µM) for 24 h, followed by treatment with TRAIL (50 nM) for another 24 h. Cell viability was 
measured at the end of 48 h by XTT assay. (C), PC-3 cells were seeded in soft agar and treated with curcumin (5–40 µM) in 
the presence or absence of TRAIL (25 nM). After three weeks, no of colonies were counted. Data represent mean ± SE. (D), 
LNCaP cells were seeded in soft agar and treated with curcumin (5–40 µM) in the presence or absence of TRAIL (50 nM). 
After three weeks, no of colonies were counted. Data represent mean ± SE. (E and F), Effects of dominant negative FADD on 
curcumin and/or TRAIL-induced apoptosis. PC-3 and LNCaP cells were transiently transfected with either control plasmid or 
plasmid expressing dominant negative FADD (DN-FADD) along with plasmid (pCMV-LacZ) encoding the β-galactosidase (β-
Gal) enzyme. There was no difference in transfection efficiency among groups. Transfected cells were treated with curcumin 
(0, 10 or 20 µM) in the presence or absence of TRAIL (25 nM for PC-3 cells or 50 nM for LNCaP) for 48 h. Apoptosis was 
measured by DAPI staining. Data represent mean ± SE. * = significantly different from respective control; # and % = treatment 
groups were significantly different, P < 0.05.Page 3 of 14
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Activation of death receptors (TRAIL-R1/DR4 and TRAIL-
R2/DR5) by TRAIL transmits caspase-dependent apopto-
sis signal [35]. We have recently shown that chemothera-
peutic drugs, histone deacetylase inhibitors and γ-
irradiation upregulate death receptors DR4 and/or DR5,
and thus enhance the effectiveness of TRAIL
[22,23,33,34,36,37]. Since curcumin enhances the apop-
tosis-inducing potential of TRAIL, we measured the
expression of cell surface death receptors by flowcytome-
try (Fig. 2 and 3). Curcumin had no significant effect on
the expression of DcR1 and DcR2 in PC-3 (Fig. 2) and
LNCaP (Fig. 3) cells. By comparison, treatment of these
cells with curcumin resulted in an increased expression of
DR4 and DR5 in both cell lines. These data suggest that
upregulation of death receptor DR4 and DR5 by curcumin
may enhance the apoptosis-inducing potential of TRAIL
in PC-3 and LNCaP cells.
Regulation of Bcl-2 family members by curcumin
Bcl-2 family members regulate apoptosis induced by
stress stimuli primarily at the level of mitochondria
[34,38,39]. We, therefore, examined the effects of curcu-
min on the expression of Bcl-2 family members. The West-
ern blot analysis showed that curcumin induced
expression of pro-apoptotic proteins Bak, Bax, PUMA,
Bim and Noxa, and inhibited expression of anti-apoptotic
protein Bcl-XL and Bcl-2 in PC-3 cells (Fig. 4A). It is impor-
tant to note that the expression of BimL isoform was sig-
nificantly higher with all the doses of curcumin treatment
at 48 h compared to control. The cleavage of Bcl-2 family
member Bid to tBid (truncated Bid) is essential for linking
death receptor pathway to mitochondrial pathway. We
therefore measured whether curcumin treatment causes
cleavage of Bid. Treatment of PC-3 cells with curcumin
resulted in cleavage of Bid to tBid. Similarly, curcumin
induced expression of Bak, Bax, PUMA, Bim and Noxa,
and inhibited expression of Bcl-XL and Bcl-2 in LNCaP
cells (Fig. 4B). Furthermore, Bid was cleaved by curcumin
in LNCaP cells. These data suggest that Bcl-2 family mem-
bers may regulate sensitivity of prostate cancer cells to cur-
cumin and/or TRAIL.
Inhibition of XIAP and survivin by curcumin
Inhibitors of apoptosis proteins (IAPs) play a major role
in inhibiting caspase activation and apoptosis [40]. Since
curcumin augments TRAIL-induced apoptosis by activa-
tion of caspases, we sought to examine the effects of cur-
cumin on the expression of IAPs (XIAP, survivin, cIAP1
and cIAP2) in PC-3 and LNCaP cells (Fig. 4C and 4D).
Effects of curcumin on cell surface expression of death receptorsFigure 2
Effects of curcumin on cell surface expression of death receptors. PC-3 cells were treated with curcumin (0, 10 and 
20 µM) for 24 h, and the expression of DcR1, DcR2, DR4, and DR5 was measured by flowcytometric analysis.Page 4 of 14
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expressions of IAPs were measured by the Western blot
analysis. Curcumin inhibited expression of survivin and
XIAP, and had no effect on levels of cIAP1 and cIAP2 in
both PC-3 and LNCaP cells. These data suggest that inhi-
bition/cleavage of IAPs by curcumin may be one of the
mechanisms regulating apoptosis.
Interactive effects of curcumin and TRAIL on 
mitochondrial membrane potential
During apoptosis, engagement of the mitochondrial path-
way involves the permeabilization of the outer mitochon-
drial membrane (OMM), which leads to the release of
proteins such as cytochrome c and Smac/DIABLO [41].
OMM permeabilization depends on activation, transloca-
tion and oligomerization of multidomain Bcl-2 family
proteins such as Bax or Bak. We have shown that curcu-
min causes drop in mitochondrial membrane potential
(∆Ψm), and release of Smac/DIABLO, cytochrome c and
Omi/HtrA2 from mitochondria to cytosol in prostate can-
cer cells [12]. Curcumin treatment of PC-3 and LNCaP
cells caused a drop in ∆Ψm in a time-dependent manner
(Fig. 5A and 5B). Treatment of these cells with curcumin,
TRAIL or curcumin plus TRAIL had no effect on mito-
chondrial membrane potential at 0 h (Fig. 5C and 5D). In
PC-3 cells, curcumin and TRAIL alone caused a ∆Ψm at
both 8 and 16 h (Fig. 5C). The combination of curcumin
and TRAIL had enhanced loss of ∆Ψm when compared
with either agent alone. In LNCaP cells, although TRAIL
alone was ineffective in reducing ∆Ψm, in combination
with curcumin it caused significant loss of ∆Ψm(Fig. 5D).
These data suggest that curcumin exerts antiproliferative
effects at the level of mitochondria.
Curcumin augments TRAIL-induced apoptosis through 
caspase activation
The apoptotic death of cells requires proteolytic activation
of caspases which are synthesized as latent proenzymes.
Once activated, caspases cleave a wide range of molecules
(e.g. PARP) that eventually result in the dismantlement of
cells. Active caspases can be specifically inhibited by
inhibitors of apoptosis (IAP). IAP antagonists such as
Smac/DIABLO and Omi/HtrA2 compete with caspases for
IAP-binding and consequently relieve caspase inhibition
by IAPs and promote cell death. Since curcumin augments
TRAIL-induced apoptosis, we sought to examine the acti-
Effects of curcumin on cell surface expression of death receptorsFigure 3
Effects of curcumin on cell surface expression of death receptors. LNCaP cells were treated with curcumin (0, 10 and 
20 µM) for 24 h, and the expression of DcR1, DcR2, DR4, and DR5 was measured by flowcytometric analysis.Page 5 of 14
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Curcumin induced caspase-3 activity in PC-3 and LNCaP
cells (Fig. 6A and 6B). TRAIL induced caspase-3 activity in
PC-3 cells, but had no effect in LNCaP cells. Curcumin has
no effect on caspase-8 activity in PC-3 and LNCaP cells
(Fig. 6C and 6D). However, TRAIL induced caspase-8
activity in PC-3 cells but not in LNCaP cells. Interestingly,
the combination of curcumin and TRAIL resulted in more
caspase-3 and caspase-8 activities in both cells lines (Fig.
6A–D).
PC-3 and LNCaP cells were treated with curcumin for 24
h followed by treatment with TRAIL for another 24 h, and
the cleavage of caspase-3, caspase-9, caspase-8, and PARP
was determined. Treatment of PC-3 cells with curcumin
slightly increased caspase-3, caspase-9, caspase-8, and
PARP cleavage (Fig. 6E). The combination of curcumin
and TRAIL enhanced the cleavage of caspase-3, caspase-9,
caspase-8 and PARP in PC-3 cells. In LNCaP cells, curcu-
min induced cleavage of capase-3, caspase-9, caspase-8
and PARP, whereas TRAIL had no effect on the cleavage of
these proteins (Fig. 6F). Interestingly, pretreatment of cur-
cumin with TRAIL resulted in cleavage of capase-3, cas-
pase-9, caspase-8 and PARP. These data suggest that
curcumin induces apoptosis through caspase activation. It
Effects of curcumin on the expression of Bcl-2 family members, and inhibitors of apoptosis proteins (IAPs)Figure 4
Effects of curcumin on the expression of Bcl-2 family members, and inhibitors of apoptosis proteins (IAPs). (A 
and B), PC-3 and LNCaP cells were treated with or without curcumin (0, 5, 10 and 20 µM) for 24 or 48 h, and the expression 
of Bcl-2 family members (Bak, Bax, PUMA, Bim, Noxa, Bcl-XL, Bcl-2 and Bid) was measured by the Western blot analysis. β-
actin was used as a loading control. (C and D), PC-3 and LNCaP cells were treated with or without curcumin (0, 5, 10 and 20 
µM) for 24 or 48 h, and the expression of IAPs (cIAP1, cIAP2, survivin and XIAP) was measured by the Western blot analysis. 
β-actin was used as a loading control.Page 6 of 14
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more robust in the case of caspase-8 and PARP cleavage.
Curcumin inhibits capillary tube formation by blocking 
ERK activity
Because curcumin treatment significantly decreased
HUVEC viability, we sought to examine whether curcu-
min inhibited in vitro angiogenesis. We explored this pos-
sibility by determining the effect of curcumin treatment
on capillary tube formation by HUVEC on growth factor-
reduced matrigel, which is well-accepted technique to
measure in vitro angiogenesis [42]. The data revealed that
curcumin inhibited capillary tube formation in a dose-
dependent manner (Fig. 7A). We next examined the
involvement of ERK on capillary tube formation by using
a specific inhibitor of ERK pathway. As shown in Fig. 7B
and 7C, curcumin and ERK inhibitor alone inhibited cap-
illary tube formation, and this effect of curcumin was fur-
ther enhanced in the presence of ERK inhibitor. These
results indicated that curcumin inhibition of capillary
tube formation involved ERK MAP kinase.
Curcumin inhibits migration of HUVEC cells through ERK 
inhibition
Next we determined the effect of curcumin treatment on
invasion potential (migration) of HUVEC cells using a
modified Boyden Chamber assay. In DMSO-treated con-
trols, a large fraction of HUVEC migrated to the bottom
face of the membrane (Fig. 7D and 7E). Treatment of
chambers with curcumin resulted in inhibition of migra-
tion of HUVECs in a dose-dependent manner (Fig. 7D).
Inhibition of ERK blocked migration of HUVEC cells, and
the inhibitory effects of curcumin on cell migration were
further enhanced in the presence of ERK inhibitor (Fig.
7E). These results indicated that the migration by HUVEC
cells was inhibited by curcumin, and ERK is an important
regulator of this process.
Effects of curcumin on mitochondrial membrane potentialFigure 5
Effects of curcumin on mitochondrial membrane potential. (A and B), Curcumin induces drop in mitochondrial mem-
brane potential (∆ψm). PC-3 and LNCaP cells were treated with or without curcumin (20 µM) for 0–24 h. Cells were stained 
with JC1 dye, and ∆ψm was measured by fluorometer as per manufacturer's instructions. (C and D), Interactive effects of cur-
cumin and TRAIL on ∆ψm. PC-3 and LNCaP cells were treated with or without curcumin (20 µM) in the presence or absence 
of TRAIL for 0, 8, or 16 h. Cells were stained with JC1 dye to measure ∆ψm. * = significantly different from respective control 
(P < 0.05).Page 7 of 14
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In the present study, we have shown that curcumin
induces apoptosis in TRAIL-sensitive PC-3 cells, and sen-
sitizes TRAIL-resistant LNCaP cells through activation of
multiple signaling pathways. Curcumin-induced apopto-
sis engages mitochondria, which was evident by drop in
mitochondrial membrane potential and activation of cas-
pase-3 and caspase-9 in both androgen insensitive PC-3
and androgen-sensitive LNCaP cells. Curcumin induces
expression of proapoptotic proteins (Bax, Bak, PUMA,
Noxa and Bim), death receptors (TRAIL-R1/DR4 and
TRAIL-R2/DR5), and inhibited expression of antiapop-
totic proteins (Bcl-2 and Bcl-XL) and IAPs (XIAP and sur-
vivin). These proteins have been shown to regulate cell-
intrinsic and/or cell-extrinsic pathways of apoptosis, and
may be responsible for sensitization of TRAIL-resistant
LNCaP cells.
Our recent studies have shown that curcumin downregu-
lated the expression of Bcl-2, and Bcl-XL and upregulated
the expression of p53, Bax, Bak, PUMA, Noxa, and Bim at
mRNA and protein levels in prostate cancer cells [12]. We
also showed that curcumin upregulated the expression,
phosphorylation, and acetylation of p53 in androgen-sen-
Interactive effects of curcumin and TRAIL on caspase activation and PARP cleavageFigure 6
Interactive effects of curcumin and TRAIL on caspase activation and PARP cleavage. (A and B), PC-3 and LNCaP 
cells were treated with curcumin (0–40 µM), in the presence or absence of TRAIL, and caspase-3 activity was measured by 
fluorometric assay as per manufacturer's instructions. (C and D), PC-3 and LNCaP cells were treated with curcumin (0–40 
µM), in the presence or absence of TRAIL, and caspase-8 activity was measured by fluorometric assay as per manufacturer's 
instructions. (E and F), PC-3 and LNCaP cells were treated with curcumin (0, 10 or 20 µM), in the presence or absence of 
TRAIL (25 nM for PC-3, and 50 nM for LNCaP), and the cleavage of caspase-3, caspase-9, caspase-8 and PARP was measured 
by the Western blot analysis. β-actin was used as a loading control.Page 8 of 14
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gene transcription was also evident as it caused acetyla-
tion of histone H3 and H4 in LNCaP cells [12]. Further-
more, treatment of LNCaP cells with curcumin resulted in
translocation of Bax and p53 to mitochondria, produc-
tion of reactive oxygen species, drop in mitochondrial
membrane potential, release of mitochondrial proteins
(cytochrome c, Smac/DIABLO and Omi/HtrA2), and acti-
vation of caspase-3 leading to apoptosis [12]. In another
study, we have demonstrated that deletion of Bax and Bak
genes completely inhibited curcumin-induced cyto-
chrome c and Smac/DIABLO release in mouse embryonic
Curcumin inhibits capillary tube formation and migration of HUVEC cellsFigure 7
Curcumin inhibits capillary tube formation and migration of HUVEC cells. (A), HUVECs were seeded in 24-well 
plates containing matrigel, and treated with various concentrations of curcumin for 24 h. Capillary tubes were counted under a 
microscope. Data represent mean ± SD. * = significantly different from control, P < 0.05. (B), HUVECs were seeded in 24-well 
plates containing matrigel. Cells were pretreated with ERK inhibitor (10 µM) for 3 h, followed by treatment with curcumin (40 
µM) for 24 h. Capillary tubes were counted under a microscope. Data represent mean ± SD. * = significantly different from 
control, P < 0.05. (C), Picture of capillary tube formation. HUVECs were treated as described in B. Pictures of capillary tubes 
were taken by a microscope. (D), HUVECs were treated with various concentrations of curcumin (20, 40 and 60 µM) or 
DMSO (control). Migration of HUVEC cells through the membrane was determined after 24 h of incubation at 37°C using 
Transwell Boyden chamber. Cells that had migrated to the lower chamber were fixed with 90% ethanol, stained with hematox-
ylin and eosin, quantified by counting the number of cells under a microscope. Data represent mean ± SD. * = significantly dif-
ferent from control, P < 0.05. (E), HUVECs were pretreated with ERK inhibitor (10 µM) for 3 h, followed by treatment with 
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ostasis by curcumin suggests that it can engage cell-intrin-
sic pathway of apoptosis.
We have shown that activation of death receptor pathway
by TRAIL plays a major role in apoptosis [25,35]. The
upregulation of death receptors by chemotherapeutic
drugs, irradiation and chemopreventive agents have been
shown to sensitize cancer cells to TRAIL treatment [23-
25,33,34,36,37]. In the present study, we have demon-
strated that curcumin enhances the therapeutic potential
of TRAIL in PC-3 cells and sensitizes TRAIL-resistant
LNCaP cells by upregulating DR4 and DR5, and regulat-
ing Bcl-2 family members and IAPs. Furthermore, curcu-
min potentiates the apoptotic effects of chemotherapeutic
agents and cytokines through down-regulation of NFκB
and NFκB-regulated gene products in bladder cancer [16],
prostate cancer [43], and ovarian caner [21]. TNF-induced
NFκB-regulated gene products involved in cellular prolif-
eration (cyclooxygenase-2, cyclin D1, and c-myc), antiap-
optosis [inhibitor of apoptosis protein (IAP)1, IAP2, X-
chromosome-linked IAP (XIAP), Bcl-2, Bcl-XL, Bfl-1/A1,
TNF receptor-associated factor 1, and cellular Fas-associ-
ated death domain protein-like interleukin-1beta-con-
verting enzyme inhibitory protein-like inhibitory
protein], and metastasis (vascular endothelial growth fac-
tor, matrix metalloproteinase-9, and intercellular adhe-
sion molecule-1) were also down-regulated by curcumin
[7]. These findings suggest that curcumin, in addition to
activating cell-intrinsic pathway, can regulate cell-extrinsic
(death receptor) pathway of apoptosis and may circum-
vent chemoresistance to conventional chemotherapeutic
agents or TRAIL. We have also demonstrated that another
chemopreventive agent resveratrol enhanced the apopto-
sis-inducing potential of TRAIL in PC-3 cells [44] and sen-
sitized TRAIL-resistant LNCaP cells [45] by engaging both
cell-intrinsic and cell-extrinsic pathways of apoptosis.
The serine/threonine kinase Akt/PKB has been considered
an attractive target for cancer therapy and prevention [46].
Akt kinase plays critical roles in mammalian cell survival
and is constitutively active in various cancers [12,46-48].
We have recently shown that curcumin upregulates the
expression, phosphorylation (at serine 15) and acetyla-
tion of p53 [12]. Treatment of LNCaP cells with curcumin
results in translocation of Bax and p53 to mitochondria,
production of reactive oxygen species, drop in mitochon-
drial membrane potential, release of mitochondrial pro-
teins (cytochrome c, Smac/DIABLO and Omi/HtrA2),
activation of caspase-3 and induction of apoptosis [12].
Furthermore, curcumin inhibits expression of phosphati-
dylinositol-3 kinase (PI3K), and phosphorylation of Ser
473 Akt. Downregulation of Akt by inhibitors of PI3K
(Wortmannin and LY294002) and Akt, or by dominant
negative Akt increases curcumin-induced apoptosis,
whereas transfection of constitutively active Akt attenu-
ates this effect. Similarly, wild type phosphatase and
tensin homolog deleted from chromosome 10 (PTEN)
enhances curcumin-induced apoptosis. Furthermore,
overexpression of constitutively active Akt inhibits curcu-
min-induced p53 translocation to mitochondria, and
Smac release to cytoplasm, whereas inhibition of Akt by
dominant negative Akt enhances curcumin-induced p53
translocation to mitochondria and Smac release [12].
These studies establish a role for Akt in modulating the
direct action of p53 on the caspase-dependent mitochon-
drial death pathway and suggest that these important bio-
logical molecules interact at the level of the mitochondria
to influence curcumin sensitivity. We have also demon-
strated that curcumin causes acetylation of histone H3
and H4 in prostate cancer cells [12], suggesting histone
modification may regulate gene transcription related to
cell growth, differentiation and apoptosis.
Activation of the Raf-MEK-ERK signal transduction path-
way in endothelial cells is required for angiogenesis [49].
Activating mutations in RAS and RAF result in inappropri-
ate activation of downstream kinases, mitogen-activated
protein kinase kinase (MEK) and extracellular signal-regu-
lated kinase (ERK), and deregulated mitogenic and cell
survival signaling [50]. The frequent derangement of these
molecules in human cancers provides the rationale for
their inhibition by pharmacological approaches. Our
studies demonstrate that curcumin can inhibit capillary
tube formation and endothelial cell migration, and these
effects can be enhanced by MEK inhibitor. Curcumin has
been shown to inhibit the expression genes involved in
angiogenesis and metastasis (VEGF, ICAM-1, CD31,
MMP-9) [7,9,10,15]. Thus, curcumin can inhibit tumor
growth by inhibiting angiogenesis.
Curcumin has been shown to inhibit neoplastic initia-
tion, promotion, and progression in several cancers. Cur-
cumin inhibits tumor formation induced by
ben(a)pyrene(BP), and 7,12-dimethylbenz(a)antracen
(DMBA) in mouse model of gastric and skin tumors,
respectively [51-53]. Furthermore, the administration of
4% curcumin in the diet of azoxymethane-treated mice
reduced the number of colon tumors by 66% [54]. The
clinical significance of curcumin in vivo is not yet clear.
Data regarding the pharmacokinetics of curcumin suggest
that there is a poor bioavailability in humans due to its
rapid metabolism in the liver and intestinal wall, when
taken orally [5,55-57]. Piperine has been shown to
increase the bioavailability of curcumin by 2000% [58].
Curcumin significantly inhibited the cellular production
of proinflammatory mediators such as TNFα and nitric
oxide, and significantly inhibited the release of MCP-1
from adipocytes [59]. Curcumin can suppress obesity-
induced inflammatory responses by suppressing adiposePage 10 of 14
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iting MCP-1 release from adipocytes, and thus it may have
a potential to improve chronic inflammatory conditions
in obesity. Curcumin is currently in clinical trials for the
treatment of various cancers [57] and for Alzheimer's dis-
ease.
Conclusion
Our study shows that curcumin enhances the apoptosis-
inducing potential of TRAIL in PC-3 cells and sensitizes
TRAIL-resistant LNCaP cells through multiple mecha-
nisms. It induces death receptors, upregulates proapop-
totic members of Bcl-2 family (Bax, Bak, Noxa, PUMA),
inhibits antiapoptotic Bcl-2 proteins (Bcl-2 and Bcl-XL),
IAPs (survivin, XIAP), and activates caspase-3, and cas-
pase-9. The ability of curcumin to disrupt mitochondrial
homeostasis may also be due to generation of reactive
oxygen species as we have suggested previously [12]. Since
curcumin activates both cell-intrinsic and – extrinsic path-
ways of apoptosis, it has enormous therapeutic potential.
In addition to apoptosis, curcumin also inhibited capil-
lary tube formation and invasion by blocking ERK. All
these events will significantly contribute to the antiprolif-
erative and antitumor activities of curcumin. Because cur-
cumin has potent cytotoxic effects in vitro, especially in
combination with TRAIL, studies to evaluate the efficacy
of this combination in a suitable mouse model are war-
ranted. Our studies strongly demonstrate that curcumin
either alone or in combination with TRAIL can be used for
prevention and/or treatment of prostate cancer.
Methods
Reagents
Antibodies against cIAP1, cIAP2, survivin, XIAP, Bcl-2,
Bcl-XL, Bax, Bak, Bid, PUMA, Noxa, Bim, and β-actin were
purchased from Santa Cruz Biotechnology Inc. (Santa
Cruz, CA). Anti-caspae-3, anti-caspase-8, anti-caspase-9,
and anti-PARP antibodies were purchased from BD Bio-
sciences/Pharmingen (San Diego, CA). JC-1 was pur-
chased from Invitrogen/Molecular Probes, Inc. (Eugene,
OR). Enhanced chemiluminescence (ECL) Western blot
detection reagents were from Amersham Life Sciences Inc.
(Arlington Heights, IL). MEK1/2 inhibitor PD98059, and
kits for Terminal Deoxynucleotidyl Transferase Biotin-
dUTP Nick End Labeling (TUNEL), caspase-3 and caspase-
8 assays were purchased from EMD Biosciences/Calbio-
chem (San Diego, CA). Antibodies against TRAIL-R1/
DR4, TRAIL-R2/DR5, DcR1, and DcR2 for flowcytometry
were purchased from R&D Systems, Inc. (Minneapolis,
MN). TRAIL was purified as described elsewhere [60].
Curcumin was purchased from LKT Laboratories, Inc. (St.
Paul, MN).
Cell culture
Androgen-sensitive LNCaP and androgen-insensitive PC-
3 cell lines from human prostate cancer were obtained
from the American Type Culture Collection (Manassas,
VA). Cultures were maintained in RPMI 1640 supple-
mented with 10% heat-inactivated fetal bovine serum
(FBS) and 1% antibiotic-antimycotic (Invitrogen) at 37°C
in a humidified atmosphere of 95% air and 5% CO2.
Human umbilical vein endothelial cells (HUVECs) were
purchased from Clonetics (Walkersville, MD) and main-
tained in endothelial cell growth factor medium-2 (EGM2
MV SingleQuots, Clonetics) supplemented with 5% FBS.
The effect of curcumin on HUVEC viability was deter-
mined by trypan blue dye exclusion assay.
XTT assay
Cell growth inhibition was analyzed by the spectrophoto-
metric measurement of the mitochondrial dehydrogenase
activity using 2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-
5-[(phenylamino) carbonyl]-2H-tetrazo-lium hydroxide
(XTT). XTT is converted to a colored formazan in the pres-
ence of metabolic activity (the primary mechanisms of
XTT-to-formazan conversion are the mitochondrial succi-
noxidase and cytochrome P450 systems, as well as flavo-
protein oxidases). Since the formazan product is water
soluble, it is easily measured in cellular supernatants.
Prostate cancer cells (1 × 104 in 200 µl culture medium per
well) were seeded in 96-well plate (flat bottom), treated
with or without drugs and incubated for various time
points at 37°C and 5% CO2. Before the end of the exper-
iment, 50 µl XTT labeling mixture (final concentration,
125 µM sodium XTT and 25 µM PMS) per well was added
and plates were incubated for further 4 h at 37°C and 5%
CO2. The spectrophotometric absorbance of the sample
was measured using a microtitre plate (ELISA) reader. The
wavelength to measure absorbance of the formazon prod-
uct was 450 nm, and the reference wavelength was 650
nm.
Colony formation assay
Prostate cancer cells were seeded on soft agar at a density
of 500 per well in a six-well plate containing 1 ml of
RPMI/10% fetal bovine serum. Cells were then incubated
at 37°C in a humidified atmosphere containing 5% CO2.
Colony growth was assessed by the size and number of
colonies after three weeks. Colonies exceeding the mini-
mum diameter of 80 µm were counted.
Measurement of apoptosis
Apoptosis was measured by the terminal deoxynucleoti-
dyl transferase-mediated nick end-labeling method,
which examines DNA strand breaks during apoptosis.
Briefly, 1 × 105 cells were treated with curcumin and/or
TRAIL at the indicated doses for various time points at
37°C. Thereafter, cells were washed with PBS, air-dried,Page 11 of 14
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with 0.1% Triton X-100 in 0.1% sodium citrate. After
washing, cells were incubated with reaction mixture for 60
minutes at 37°C. Stained cells were mounted and ana-
lyzed under a microscope. In some cases, the data were
confirmed by staining cells with Hoechst 33248.
Capillary tube formation assay
Capillary tube formation assays were performed as we
described earlier [61]. In brief, matrigel (100 µl) was
added to wells of a 96-well culture plate and allowed to
polymerize for 1 h at 37°C. To examine the effects of cur-
cumin on in vitro angiogenesis, subconfluent HUVECs
were resuspended in complete medium and added to
matrigel containing wells (1 × 104 cells/well), and
exposed to various concentrations of curcumin, MEK1/2
inhibitor (PD098059) or DMSO (control). The plates
were incubated at 37°C in a humidified atmosphere of
95% air and 5% CO2 [62]. Capillary tube formations
(tubular structure formations) on 3-D Matrigel were visu-
alized after 24 h under an inverted phase-contrast micro-
scope (×200), and photomicrographs were documented
by a SPOT digital camera (Sterling Heights, MI). Tube for-
mation was defined as straight cellular extensions joining
two cell masses or at branch points.
In vitro cell migration (invasion) assay
Cell migration assays were performed as we described ear-
lier [61]. In brief, migration of HUVEC cells was assessed
using Transwell Boyden chamber (Corning, Acton, MA)
containing a polycarbonated filter with a pore size of 8-
µM. HUVECs (4 × 104 cells in 0.2 ml) cells in complete
medium was mixed with desired concentration of curcu-
min, MEK1/2 inhibitor (PD098059) or DMSO (control),
and the cell suspension was added to the upper chamber.
The lower chamber contained 0.6 ml of complete
medium with the same concentration of curcumin, ERK
inhibitor or DMSO. Migration through the membrane
was determined after 24 h of incubation at 37°C. Cells
remaining on the topside of the transwell membrane were
removed using a cotton swab. The membrane was washed
with ice-cold PBS. Cells that had migrated to the under-
side were fixed with 90% ethanol and stained with hema-
toxylin and eosin. Cell migration was quantified by
counting the number of cells per field.
Assays for caspase-3 and caspase-8 activities
Cells (4 × 104 per well) were seeded in a 96-well plate with
200 µl culture medium. Approximately 16 h later, cells
were treated with various doses of curcumin and/or TRAIL
to induce apoptosis. Casapse-3 and caspase-8 activities
were measured as per manufacturer's instructions (EMD
Biosciences) with a fluorometer.
Western blot analysis
Cell pellets were lysed in RIPA buffer containing 1 × pro-
tease inhibitor cocktail, and protein concentrations were
determined using the Bradford assay (Bio-Rad, Philadel-
phia, PA). Cell lysates were electrophoresed in 12.5% SDS
polyacrylamide gels and then transferred onto nitrocellu-
lose membranes. After blotting in 5% nonfat dry milk in
TBS, the membranes were incubated with primary anti-
bodies at 1:1,000 dilution in TBS-Tween 20 overnight at
4°C, and then secondary antibodies conjugated with
horseradish peroxidase at 1:5,000 dilution in TBS-Tween
20 for 1 hour at room temperature. Protein bands were
visualized on X-ray film using an enhanced chemilumi-
nescence system.
Measurement of mitochondrial membrane potential 
(∆Ψm)
Mitochondrial energization was determined by retention
of JC-1 dye (Molecular Probes Inc., Eugene) as we
described earlier [22,63]. Briefly, drug treated cells (5 ×
105) were loaded with JC-1 dye (1 µg/ml) during the last
30 min of incubation at 37°C in a 5% CO2 incubator.
Cells were washed in PBS twice. Fluorescence was moni-
tored in a fluorometer using 570-nm excitation/595-nm
emission for the J-aggregate of JC1 [64]. ∆Ψm was calcu-
lated as a ratio of the fluorescence of J-aggregate (aqueous
phase) and monomer (membrane-bound) forms of JC1.
Statistical analysis
The mean and SD were calculated for each experimental
group. Differences between groups were analyzed by one
or two way ANOVA using PRISM statistical analysis soft-
ware (GrafPad Software, Inc., San Diego, CA). Significant
differences among groups were calculated at P < 0.05.
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